INFLUENCE OF CERTAIN H1-BLOCKERS ON THE STEP-THROUGH ACTIVE-AVOIDANCE RESPONSE IN RATS

被引：70

作者：

KAMEI, C ^{[1
]}

CHUNG, YH ^{[1
]}

TASAKA, K ^{[1
]}

机构：

[1] OKAYAMA UNIV,FAC PHARMACEUT SCI,DEPT PHARMACOL,OKAYAMA 700,JAPAN

来源：

PSYCHOPHARMACOLOGY | 1990年 / 102卷 / 03期

关键词：

Acquisition; Active avoidance; Chronic administration; H[!sub]1[!/sub]-blockers; Rat; Retention;

D O I：

10.1007/BF02244096

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The inhibitory effects of some newly developed H1-blockers on the step-through active avoidance response in rats were studied in comparison with those of classical H1-blockers. Single administration of diphenhydramine, pyrilamine, promethazine and chlorpheniramine caused dose-related depressant effects on the active avoidance response. Ketotifen and azelastine caused less potent inhibition than the classical H1-blockers, while the effects of astemizole and oxatomide were almost negligible in suppressing the response. Following chronic administration of pyrilamine and promethazine, the acquisition of active avoidance response was significantly retarded compared with the control group, where-as new H1-blockers caused a somewhat but not significantly slower acquisition than the control group. Chronic administration of astemizole and oxatomide caused only transient suppression of the response. However, classical H1-blockers such as pyrilamine and promethazine caused sustained inhibition for as long as drug administration was continued. © 1990 Springer-Verlag.

引用

页码：312 / 318

页数：7

共 27 条

[1] SELECTIVE DISPLACEMENT OF [H-3] MEPYRAMINE FROM PERIPHERAL VS CENTRAL-NERVOUS-SYSTEM RECEPTORS BY LORATADINE, A NONSEDATING ANTIHISTAMINE [J].

AHN, HS ;

BARNETT, A .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 127 (1-2) :153-155

[2] INHIBITION OF PASSIVE CUTANEOUS ANAPHYLAXIS (PCA) BY AZELASTINE - DISSOCIATION OF ITS ANTIALLERGIC ACTIVITIES FROM ANTIHISTAMINIC AND ANTISEROTONIN PROPERTIES [J].

CHAND, N ;

HARRISON, JE ;

ROONEY, SM ;

SOFIA, RD ;

DIAMANTIS, W .

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1985, 7 (06) :833-838

[3]

DOUGLAS WW, 1985, PHARMACOL BASIS THER, P618

[4]

Ganellin C. R., 1982, CHEM STRUCTURE ACTIV, P10

[5]

HOLGATE ST, 1988, ASTEMIZOLE REV CLIN, P1

[6]

KANEKO T, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1206

[7]

LADURON PM, 1983, S SERIES, V11, P11

[8]

LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99

[9]

MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770

[10]

MCKEARNEY JW, 1982, J PHARMACOL EXP THER, V222, P215

← 1 2 3 →